ABSTRAK
INTRODUCTION
Tissue ischemia reperfusion (IR) remain of the main causes of permanent or transient damage with serious implications on adjacent organs and certainly on patients' health. Although important progress has been made regarding the usage of erythropoietin (Epo) in managing this kind of damages, satisfactory answers have not been given yet to fundamental questions, as, by what velocity this factor acts, when should it be administered, and in which dosage. The particularly satisfactory action of Epo in stem blood cells recovery has been noted in several performed experiments. However, just few relative reports were found concerning Epo trial in IR experiments, not covering completely this particular matter. A meta-analysis of 13 published seric variables, coming from the same experimental setting, tried to provide a numeric evaluation of the Epo efficacy at the same endpoints (Table 1) (Tsompos et al 2015a , Tsompos et al 2015b . Furthermore, several publications addressed trials of other similar molecules of growth factors to which the studied molecule also belongs to (Bader et al 2011 , Wang et al 2011 . The aim of this experimental study was to examine the effect of Epo on rat model and particularly in a pancreas IR protocol. The effect of that molecule was studied by measuring the blood mean glucose (Gl) levels.
MATERIALS AND METHODS

Animal preparation
This experimental study was lisenced by Veterinary Address of East Attiki Prefecture under 3693/12-11-2010 & 14/10-1-2012 decisions. All settings needed for the study including consumables, equipment and substances used, were a courtesy of Exprerimental Research Center of ELPEN Pharmaceuticals Co. Inc. S.A. at Pikermi, Attiki. Accepted standards of humane animal care were adopted for Albino female Wistar rats. Normal housing in laboratory 7 days before the experiment included continuous access to water and food. The experiment was acute, that means that awakening and preservation of the rodents was not following the experiment. They were randomly delivered to four experimental groups by 10 animals in each one. Ischemia for 45 min followed by reperfusion for 60 min (group A). Ischemia for 45 min followed by reperfusion for 120 min (group B). Ischemia for 45 min followed by immediate Epo intravenous (IV) administration and reperfusion for 60 min (group C). Ischemia for 45 min followed by immediate Epo IV administration and reperfusion for 120 min (group D). The molecule Epo dosage was 10 mg/Kg body weight of animals.
At first, the animals were submitted into prenarcosis followed by general anesthesia. The detailed anesthesiologic technique is described in related references (Tsompos et al 2015a , Tsompos et al 2015b . Oxygen supply, electrocardiogram and acidometry were continuously provided during whole experiment performance.
The protocol of IR was followed. Ischemia was caused by forceps clamping inferior aorta over renal arteries for 45 min after laparotomic access had been achieved. Reperfusion was induced by removing the clamp and reestablishment of inferior aorta patency. The molecules were administered at the time of reperfusion, through inferior vena cava after catheterization had been achieved. The Gl levels measurements were performed at 60 min of reperfusion (for groups A and C) and at 120 min of reperfusion (for groups B and D). The mean weight of the forty (40) Table  2) .
RESULTS
Weight comparison of every one from 4 rats groups initially was performed with each other from 3 remained groups applying statistical paired t-test (Table 3) . Any emerging significant difference among gl levels, was investigated whether owed in the above mentioned significant weight correlations. Gl levels comparison of every one from 4 rats groups initially was performed with each other from 3 remained groups applying statistical paired t-test (Table 3) . Applying generalized linear models (glm) with dependant variable the gl levels and independent variables the Epo administration or no, the reperfusion time and their interaction, resulted in: Epo administration non-significantly increased the gl levels by 24.75 mg/dl [-31 .36051 mg/dl -80.86051 mg/dl] (P= 0.3775). This finding was in accordance with the results of paired t-test (p=0.2642). Reperfusion time non-significantly increased the gl levels by 24.95 mg/dl [-31 .15096 mg/dl -81.05096 mg/dl] (P= 0.3736), also in accordance with paired t-test (p=0.4461). However, erythropoietin administration and reperfusion time together produced a non significant combined effect in increasing the gl levels by 22.06364 mg/dl [-11 .34881 mg/dl -55.47608 mg/dl] (P= 0.1892). Reviewing the above and table 3, the tables 4 and 5 sum up concerning the alteration influence of Epo in connection with reperfusion time. Inserting the rats weight as independent variable at glm, a non significant relation turns on gl levels (p= 0.2104), so as to further investigation is not needed. 
DISCUSSION
The following clinical situations show how hyperglycemia favors ischemia. Gąsecki et al (2012) significantly associated favorable early outcome with adjustment for blood Gl level on admission in stroke patients (P = 0.001). Nardi et al (2012) found that admission hyperglycemia (≥143mg/dL) is a strong and independent predictor for 72-hour fatality, especially in patients with no prior history of diabetes mellitus (overall: OR=4.0, p=0.003; non-diabetics: OR=4.9, p=0.004). Admission hyperglycemia increases the risk of death in first-ever acute ischemic stroke patients (Nardi et al 2012) . Yang et al (2010) found that elevated mean blood Gl (equal or greater than 7.1 -8.5 mmol/L) levels is an independent predictor and superior to admission Gl (AG) (P < 0.001) on predicting 7-and 30-day mortality and combined end point events on predicting short-term prognosis in acute myocardial infarction patients.
Also, the following situations reflect the effect Epo has on Gl levels. Lagarto et al (2012) observed a slight increase in Gl level within the normal range after 28 days of intra-nasal dosing of 6900 UI/kg/day Epo in healthy Wistar rats. Lee et al (2006) found that Gl and insulin concentrations were significantly lowered by the 25-day mountaineering activity where Epo increases, in male subjects group. Spaia et al (2000) proved the beneficial effect of Epo treatment on insulin resistance in non-obese, non-diabetic, stable dialysis patients, could be attributed to the Epo itself. Berridge & Tan (1995) showed that growth factors can still promote short term cell survival responses, increasing affinity for Gl and thus the intracellular Gl concent-ration. Kokot et al (1994) noticed an increase of fasting insulinemia and a decrease of basal plasma level of glucagon and PP after 6 months of rHuEpo treatment. At that time point rHuEpo therapy also increased the response of insulin, glucagon, and gastrin to the test meal (Kokot et al 1994) . Salvesen et al (1993) found the mean umbilical venous blood Epo significantly higher in diabetic pregnancies than the appropriate normal mean for gestation. There were significant associations between fetal hemoglobin and maternal glycosylated hemoglobin. Obviously, maternal hyperglycemia causes fetal hyperglycemia. The increase in fetal hemoglobin may be mediated by either Epo or hyperinsulinemia (Salvesen et al 1993) . Mulay & Congote (1985) found that Epo had a specific stimulatory effect on embryonictype globins in fetal liver cells in rat fetuses of diabetic mothers, which was significantly higher than control ones until 14 days of gestation. After this endpoint, these differences are abolished, but until then, a complicity between hyper-glycemia and Epo is denoted (Mulay & Congote 1985) . Katz et al (2010) demonstrated Epo-mediated decrease in blood Gl levels, attenuation of body weight gain and reduction of hemoglobin A1c in all mice models tested. Nakao et al (1998) correlated inversely the changes in HbA1c with both the changes in Hct and the reticulocyte counts by Epo treatment, though there were no significant changes in blood Gl levels during the 2-weeks study period in 15 non-diabetic hemodialysis patients.
CONCLUSION
Epo administration, reperfusion time, or their interaction non-significantly increase the blood glucose levels in short-term. The opposite bibliographic data are considered more reliable. A greater sample would provide more clearer results. Seven from nine studies show clearly that Epo has a definite declining effect on Gl levels.
